RU2003126170A - METHODS FOR INTRODUCING EPOTHYLON ANALOGUES IN THE TREATMENT OF CANCER - Google Patents
METHODS FOR INTRODUCING EPOTHYLON ANALOGUES IN THE TREATMENT OF CANCER Download PDFInfo
- Publication number
- RU2003126170A RU2003126170A RU2003126170/15A RU2003126170A RU2003126170A RU 2003126170 A RU2003126170 A RU 2003126170A RU 2003126170/15 A RU2003126170/15 A RU 2003126170/15A RU 2003126170 A RU2003126170 A RU 2003126170A RU 2003126170 A RU2003126170 A RU 2003126170A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- group
- aryl
- formula
- Prior art date
Links
- 0 *CCC(CCC*C[C@](C(*)=C*)NC(CC(C(*)(*)C(C1*)=O)O)=O)C1O Chemical compound *CCC(CCC*C[C@](C(*)=C*)NC(CC(C(*)(*)C(C1*)=O)O)=O)C1O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (77)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26422801P | 2001-01-25 | 2001-01-25 | |
US60/264,228 | 2001-01-25 | ||
US29000601P | 2001-05-11 | 2001-05-11 | |
US60/290,006 | 2001-05-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2003126170A true RU2003126170A (en) | 2005-02-27 |
RU2292202C2 RU2292202C2 (en) | 2007-01-27 |
Family
ID=26950348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003126170/15A RU2292202C2 (en) | 2001-01-25 | 2002-01-22 | Method for introducing epotilone analogs for treating cancer cases |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP4633331B2 (en) |
AU (1) | AU2002245296B2 (en) |
CA (1) | CA2434526C (en) |
HR (1) | HRP20030677B1 (en) |
IL (1) | IL156578A0 (en) |
MX (1) | MXPA03006412A (en) |
NO (1) | NO335119B1 (en) |
PL (1) | PL207720B1 (en) |
RU (1) | RU2292202C2 (en) |
WO (1) | WO2002058700A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
CN101686973B (en) * | 2007-06-01 | 2013-06-19 | 惠氏有限责任公司 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
WO2009089138A1 (en) * | 2008-01-04 | 2009-07-16 | Bristol-Myers Squibb Company | Oral administration of ixabepilone |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
JP2001510915A (en) * | 1997-07-18 | 2001-08-07 | ヒューレット・パッカード・カンパニー | Format for passing information between devices |
US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
PL201329B1 (en) * | 1998-02-05 | 2009-03-31 | Novartis Ag | Organic compounds containing compositions |
FR2775187B1 (en) * | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
DE50014587D1 (en) * | 1999-02-18 | 2007-10-04 | Bayer Schering Pharma Ag | 16-HALOGEN EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL USE |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
-
2002
- 2002-01-22 IL IL15657802A patent/IL156578A0/en not_active IP Right Cessation
- 2002-01-22 CA CA2434526A patent/CA2434526C/en not_active Expired - Lifetime
- 2002-01-22 RU RU2003126170/15A patent/RU2292202C2/en active
- 2002-01-22 AU AU2002245296A patent/AU2002245296B2/en not_active Ceased
- 2002-01-22 JP JP2002559034A patent/JP4633331B2/en not_active Expired - Fee Related
- 2002-01-22 WO PCT/US2002/001813 patent/WO2002058700A1/en active IP Right Grant
- 2002-01-22 PL PL373727A patent/PL207720B1/en unknown
- 2002-01-22 MX MXPA03006412A patent/MXPA03006412A/en active IP Right Grant
-
2003
- 2003-07-24 NO NO20033341A patent/NO335119B1/en not_active IP Right Cessation
- 2003-08-25 HR HR20030677A patent/HRP20030677B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002245296B2 (en) | 2006-12-21 |
JP4633331B2 (en) | 2011-02-16 |
CA2434526C (en) | 2011-11-01 |
RU2292202C2 (en) | 2007-01-27 |
HRP20030677A2 (en) | 2004-08-31 |
PL207720B1 (en) | 2011-01-31 |
NO20033341L (en) | 2003-09-04 |
CA2434526A1 (en) | 2002-08-01 |
MXPA03006412A (en) | 2003-10-15 |
JP2005503323A (en) | 2005-02-03 |
IL156578A0 (en) | 2004-01-04 |
NO20033341D0 (en) | 2003-07-24 |
HRP20030677B1 (en) | 2011-10-31 |
PL373727A1 (en) | 2005-09-05 |
NO335119B1 (en) | 2014-09-22 |
WO2002058700A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI296523B (en) | Formulations | |
RU2003126171A (en) | Parenteral composition containing analogs of epothilone | |
JP5670335B2 (en) | Bendamustine liquid formulation | |
HUP0302726A2 (en) | Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same | |
SK287754B6 (en) | Pharmaceutical composition, injectable solution and vial comprising parecoxib or salt thereof and process for preparing reconstitutable selective COX-2 inhibitory composition | |
US7638556B2 (en) | Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof | |
HUE030464T2 (en) | Caspofungin composition | |
CA2703044C (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy | |
US20130317048A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
US20220273613A1 (en) | Composition containing artesunate | |
RU2003126170A (en) | METHODS FOR INTRODUCING EPOTHYLON ANALOGUES IN THE TREATMENT OF CANCER | |
AU2006221633B2 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
US20040152625A1 (en) | Method for improving the pharmacokinetics of an NNRTI | |
RU2358730C2 (en) | Epothilone derivative for treatment of hepatome and other cancer diseases | |
JP2005503323A5 (en) | ||
WO2006105399A1 (en) | Methods for administering ixabepilone | |
KR20080096829A (en) | Intravenous antiviral treatments | |
KR20010092751A (en) | Medicinal compositions for treating osseous lesion in multiple myeloma | |
US20030087938A1 (en) | Treatment of chronic pain with 3-heterocycloxy-and 3-cycloalkyloxy-3-phenylpropanamines | |
JPH07196507A (en) | Rapamycin preparation for phleboclysis | |
US11400096B2 (en) | Small molecules for the treatment of autoimmune disorders | |
CN104771371B (en) | 4- (3, 5-dimethoxyphenyl) -5- (3-hydroxy-4-methoxyphenyl) imidazole preparation | |
JPH0672871A (en) | Agent for suppressing metastasis of cancer | |
JPH0296534A (en) | Use of thromboxane antagonist in cyclosporin a induced renal toxity | |
CN114364401A (en) | Method for preventing precipitation of injection containing boronophenylalanine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20190117 |
|
TK4A | Correction to the publication in the bulletin (patent) |
Free format text: CORRECTION TO CHAPTER -PC4A- IN JOURNAL 2-2019 FOR INID CODE(S) D N |